Regulatory action was based on data from the Phase III IMforte trial, which showed that Zepzelca plus Tecentriq significantly ...

FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.

Tempest Therapeutics TPST announced that the European Medicines Agency (EMA) has granted an orphan drug designation (ODD) to ...

Recent trials unveil significant advances in cancer treatment with immunotherapy drug Tecentriq, showing a 50% reduction in ...

Adding Roche's immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread ...

The Phase III IMforte study shows that adding lurbinectedin to Tecentriq for ES-SCLC first-line maintenance reduced disease ...

Several oral abstracts presented at the American Society of Clinical Oncology’s annual meeting highlight ongoing research of Keytruda, Opdivo, Tecentriq and more in skin cancer.

In the Phase III IMforte trial, Tecentriq (atezolizumab) and Zepzelca (lurbinectedin) reduced the risk of disease progression ...

Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung ...

Find insight on Roche, Bangkok Dusit Medical Services, ResMed and more in the latest Market Talks covering the health care ...

Researchers at ASCO reviewing data from the ATOMIC trial said they will change practice based on the results but questioned ...

Paradromics' Brain-Computer Interface has been tested briefly in a patient with epilepsy. Neuralink, Precision Neuroscience, and Synchron also have devices in the works. Other news looks at a ...